Alzamend Neuro Insider Sells $344,222 Worth of Shares According to SEC Filing

Alzamend Neuro, a clinical-stage biopharmaceutical company, has filed an SEC report revealing that an insider sold shares worth $344,222. The company is developing novel products for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its pipeline consists of two drug candidates: AL001, a therapeutic combination of lithium, salicylate, and L-proline, and ALZN002, a therapeutic vaccine that seeks to remove beta-amyloid from the brain.